Sonoma Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

SNOA$1.14+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025

(In thousands, except share amounts)

Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive
	Shares	Amount	Capital	Deficit	Loss	Total
Balance, March 31, 2026	1,799,057	$–	$207,319	$(200,981)	$(3,243)	$3,095
Proceeds from the At-the-Market sale of common stock, net of offering expenses	23,781	–	55	–	–	55
Proceeds from the sale of common stock, net of offering expenses	2,962,963	–	3,481	–	–	3,481
Employee stock-based compensation	–	–	58	–	–	58
Foreign currency translation adjustment	–	–	–	–	235	235
Net loss	–	–	–	(330)	–	(330)
Balance, June 30, 2026	4,785,801	$–	$210,913	$(201,311)	$(3,008)	$6,594

Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive
	Shares	Amount	Capital	Deficit	Loss	Total
Balance, March 31, 2025	1,634,265	$–	$206,593	$(197,806)	$(4,376)	$4,411
Exercise of employee stock options	8,500	–	23	–	–	23
Employee stock-based compensation	–	–	57	–	–	57
Foreign currency translation adjustment	–	–	–	–	806	806
Net loss	–	–	–	(1,241)	–	(1,241)
Balance, June 30, 2025	1,642,765	$–	$206,673	$(199,047)	$(3,570)	$4,056

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.